FDA
September 21, 2026 blogger cannabinoids, FDA, Focus Article, food safety, From The Lab, Industry Analysis, Medicial Marijuana, pharmaceutical grade, Product Development, Stop Smoking Marijuana, Stop Smoking Pot, weed, withdrawal
The cannabinoid industry has historically focused heavily on manufacturing compliance: GMPs, certificates of analysis, potency testing, contaminant testing, traceability, and state licensing. Those systems are important, and Floraworks has invested significantly in them. But when you begin evaluating an ingredient through established food and dietary supplement frameworks, you realize that manufacturing compliance is really just […]
cannabinoids, FDA, Focus Article, food safety, From The Lab, Industry Analysis, pharmaceutical grade, Product Development
April 24, 2024 blogger cannabis reform, CBD, FDA, hemp, Medicial Marijuana, NoCo Hemp Conference and Expo, regulatory, Stop Smoking Marijuana, Stop Smoking Pot, Uncategorized, weed, withdrawal
At the 10th Annual NoCo Hemp Conference and Expo, held in beautiful Estes Park, Colorado this year, educational panels included a wide array of topics covering both the fiber and industrial potentials of hemp products as well as the plant’s supplemental and dietary applications. Our attention was focused on consuming the policy and regulatory discussions […]
cannabis reform, CBD, FDA, hemp, NoCo Hemp Conference and Expo, regulatory, Uncategorized
September 6, 2023 blogger analysis, Business, cannabis, CBD, compliance, consumer, Cultivation, Epidiolex, EU, European, extraction, farm bill, FDA, Federal, FSA, government, Growing, GW Pharma, industry, International, laboratories, laboratory, Law, Legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicial Marijuana, Medicine, product, quality, regulation, Regulations, regulatory, Retail, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, test, Testing, THC, UK, Union, United Kingdom, weed, withdrawal
This is Part Three of a four-part series discussing European cannabis regulations. Click here for Part One and here for Part Two. Part Three dives into dosage, approvals and more. Stay tuned for the final Part Four, coming next week. But does CBD harm the liver? Here, it is important that we compare apples to apples. […]
analysis, Business, cannabis, CBD, compliance, consumer, Cultivation, Epidiolex, EU, European, extraction, farm bill, FDA, Federal, FSA, government, Growing, GW Pharma, industry, International, laboratories, laboratory, Law, legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicine, product, quality, regulation, Regulations, regulatory, Retail, safety, state, test, Testing, THC, UK, Union, United Kingdom
August 28, 2023 blogger american, analysis, analytics, authority, British, Business, cannabis, CBD, compliance, consumer, Cultivation, dispensary, EFSA, Epidiolex, Europe, European, export, extraction, FDA, Federal, food, government, Growing, import, industry, International, lab, laboratories, laboratory, Law, Legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicial Marijuana, Medicine, product, quality, regulation, Regulations, regulatory, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, THC, UK, Union, United Kingdom, united states, weed, withdrawal
This is Part Two of a four-part series discussing European cannabis regulations. Click here for Part One. Part Two analyzes the differences between the UK, the EU and the US. Part Three, coming next week, dives into dosage, approvals and more. Stay tuned for more. EU Regulatory Environment We Europeans look with envy at the […]
american, analysis, analytics, authority, British, Business, cannabis, CBD, compliance, consumer, Cultivation, dispensary, EFSA, Epidiolex, Europe, European, export, extraction, FDA, Federal, food, government, Growing, import, industry, International, lab, laboratories, laboratory, Law, legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicine, product, quality, regulation, Regulations, regulatory, safety, state, THC, UK, Union, United Kingdom, united states
July 10, 2023 blogger 8, analysis, analytics, Business, Business Analysis, candy, cannabis, CBD, claim, compliance, consumer, copycat, cure, delta, delta 8, drug, Edibles & Processing, FDA, Federal, food, FTC, government, Growing, Health, industry, Law, Legal, legalization, Legalize, legislation, letter, license, marijuana, market, marketing, Medical, Medicial Marijuana, Medicine, product, regulation, Regulations, regulatory, Retail, safety, snack, state, Stop Smoking Marijuana, Stop Smoking Pot, test, THC, unsub, warning, weed, withdrawal
Last week, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) sent out warning letters to six different companies for selling copycat food products that contain Delta-8 THC. In a press release published on July 5, the FDA and FTC said they sent out letters to the following companies: Delta Munchies […]
8, analysis, analytics, Business, Business Analysis, candy, cannabis, CBD, claim, compliance, consumer, copycat, cure, delta, delta 8, drug, Edibles & Processing, FDA, Federal, food, FTC, government, Growing, Health, industry, Law, legal, legalization, Legalize, legislation, letter, license, marijuana, market, marketing, Medical, Medicine, product, regulation, Regulations, regulatory, Retail, safety, snack, state, test, THC, unsub, warning
March 29, 2023 blogger analysis, analytics, announcement, Arnold & Porter, Business, Business Analysis, cannabis, CBD, civil, claim, compliance, consumer, contaminate, contamination, delta 8, Edibles & Processing, FDA, Federal, government, industry, lab, laboratories, laboratory, labs, Law, lawsuit, Legal, legalization, Legalize, legislation, letter, liability, liable, market, Medicial Marijuana, Operations, product, Product Development, quality, recall, Recreational, regulation, regulatory, Retail, risk, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, suit, test, Testing, THC, warning, weed, withdrawal
In 2022, product liability lawsuits in the cannabis/cannabidiol (CBD) industry continued to focus on levels of THC and the psychoactive ingredient in cannabis, while federal agencies continued issuing warning letters for CBD products (including CBD-infused food and dietary supplements) that made misleading medical claims. Against this backdrop of ongoing litigation and regulatory enforcement, 2022 showed […]
analysis, analytics, announcement, Arnold & Porter, Business, Business Analysis, cannabis, CBD, civil, claim, compliance, consumer, contaminate, contamination, delta 8, Edibles & Processing, FDA, Federal, government, industry, lab, laboratories, laboratory, labs, Law, lawsuit, legal, legalization, Legalize, legislation, letter, liability, liable, market, Operations, product, Product Development, quality, recall, Recreational, regulation, regulatory, Retail, risk, safety, state, suit, test, Testing, THC, warning
February 2, 2023 blogger administration, analysis, analytics, Business, Business Analysis, cannabis, CBD, compliance, Concentrates & Extracts, consumer, Cultivation, Cultivation & Growing, DEA, Dispensaries & Retail, dispensary, drug, Edibles & Processing, extraction, farm bill, FDA, Federal, food, framework, government, Growing, industry, Law, Legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicial Marijuana, Medicine, Operations, pathway, product, products, quality, Recreational, regulation, Regulations, regulatory, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, test, usda, weed, withdrawal
On December 20, 2018, Former President Trump signed the Farm Bill into law, which removed hemp-derived cannabidiol (CBD) from the Controlled Substances Act, stripped the DEA’s authority from hemp and gave states the ability to regulate hemp markets of their own, with approval from the USDA. When that Farm Bill became law, it paved the […]
administration, analysis, analytics, Business, Business Analysis, cannabis, CBD, compliance, Concentrates & Extracts, consumer, Cultivation, Cultivation & Growing, DEA, Dispensaries & Retail, dispensary, drug, Edibles & Processing, extraction, farm bill, FDA, Federal, food, framework, government, Growing, industry, Law, legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicine, Operations, pathway, product, products, quality, Recreational, regulation, Regulations, regulatory, safety, state, test, usda
December 31, 2015 blogger CBD cannabinoid, DEA, FDA, Health & Medicine, Marijuana News, Medicial Marijuana, reduced restrictions, research, Stop Smoking Marijuana, Stop Smoking Pot
Whether for greed or science, the DEA has reduced restrictions on researching the CBD cannabinoid. Last week rumor, innuendo, and hope filled the air. As the charitable season of Christmas took hold, there was a glimmer of hope that the DEA (Drug Enforcement Administration) could be on the precipice of a historic decision, downgrading the Schedule I status of […]
CBD cannabinoid, DEA, FDA, Health & Medicine, Marijuana News, reduced restrictions, research
April 9, 2014 blogger American Academy of Neurology, cannabis, FDA, medical marijuana, Medicial Marijuana, News & Articles, opiates, pot, Stop Smoking Marijuana, Stop Smoking Pot, weed, zohydro,
I It might be time for you to start explaining marijuana as “a harmful, addictive, opiate based killer that ruins lives.” The concept has labored well for legal opiate based pain relievers. Citing marijuana’s actual medical qualities has been doing little to pressure the federal government to do something. But new pain relievers, like the terrifying Zohydro, easily obtain the …continue reading through
American Academy of Neurology, cannabis, FDA, medical marijuana, News & Articles, opiates, Pot, Weed, zohydro
April 2, 2014 blogger American Academy of Neurology, cannabis, congress, FDA, federal government, medical marijuana, Medicial Marijuana, multiple sclerosis, News & Articles, opiates, Oregon Health and Science University, painkillers, pot, Sativex, Stop Smoking Marijuana, Stop Smoking Pot, weed, zohydro,
It might be time for you to start explaining marijuana as “a harmful, addictive, opiate based killer that ruins lives.” The concept has labored well for legal opiate based pain relievers. Citing marijuana’s actual medical qualities has been doing little to pressure the federal government to do something. But new pain relievers, like the terrifying Zohydro, easily obtain the eco-friendly light in the Food and drug administration despite alerts from leaders within the medical area. Even as patient recommendations and clinical research flows in highlighting the positive impact of medicinal marijuana, we’re stuck waiting around the federal government bodies meet up with the relaxation from the electorate.
A week ago, the American Academy of Neurology launched new recommendations regarding the management of ms. MS could be debilitating and effective remedies have alluded doctors for a long time. With the possible lack of consistent effectiveness around the party from the traditional remedies, many patients happen to be made to seek complementary and alternative medications (CAM). There’s formerly not been much when it comes to research concentrating on the prosperity of CAM remedies, until lately. The American Academy of Neurology is finally searching to alter that. They lately launched their findings with different overview of 291 studies and research which involve CAM remedies for MS patients.
Lead author from the review and clinical director of Or Health insurance and Science University’s Ms Center, Dr. Vijayshree Yadav, stated “This may be the first review, evidence-based recommendation, on treating MS with CAM treatments.” He continued to state “there were 29 different treatments incorporated within the recommendations. 19 studies checked out cannabis.” The types of cannabis intake analyzed, however, were using dental cannabis extract and artificial THC. Scientists discovered that these remedies were good at treating discomfort for approximately twelve months, but didn’t address the tremors frequently connected with MS.
Losing effectiveness continues to be credited with other conditions given synthetic marijuana. Patients who’ve used medications for example Sativex have regularly reported benefits that rapidly dissipate. When we would inject good sense as it were, it appears an all natural type of Sativex, say naturally growing marijuana, would without doubt be safer on our bodies. MS scientists don’t have many details on using actual marijuana because they are mostly avoided by federal law to review real cannabis. This research is among many read about this highlights the advantages of marijuana. It really makes a person question if our chosen authorities are reading through, or if they’re even literate.
 
American Academy of Neurology, cannabis, congress, FDA, federal government, medical marijuana, multiple sclerosis, News & Articles, opiates, Oregon Health and Science University, painkillers, Pot, Sativex, Weed, zohydro